AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35989865 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of drug-drug interactions (DDIs)
Number of subjects: 246
Study 35989865 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of disease progression
Number of subjects: 246
Study 35989924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging intravenous thrombolysis (IVT)
Number of subjects: 1347
Study 35989924 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior medication with Vitamin K antagonists (VKA)
Number of subjects: 1347
Study 35989924 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher admission National Institutes of Health Stroke Scale (NIHSS) score
Number of subjects: 1347
Study 35989924 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 1347
Study 35990111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-yoga intervention (two one-on-one 30-minute sessions weekly for a total of 12 sessions)
Number of subjects: 16
Study 35990326 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Diet (HP)
Number of subjects: 136
Study 35990326 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended Protein Diet (RP)
Number of subjects: 136
Study 35990326 — intervention group
Group type: COMPARATOR
Intervention: Control Diet (CON)
Number of subjects: 136
Study 35990750 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated evaluation
Number of subjects: 175
Study 35990750 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort (standard of care)
Number of subjects: 175
Study 35990945 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30 kg/m²) in non-ischemic HFpEF
Number of subjects: 3360
Study 35990945 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30 kg/m²) in ischemic HFpEF
Number of subjects: 3360
Study 35990945 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30 kg/m²) in both non-ischemic and ischemic HFpEF during short-term follow-up
Number of subjects: 3360
Study 35990945 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III obesity in ischemic HFpEF
Number of subjects: 3360
Study 35990971 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with no SMuRFs (SMuRFless)
Number of subjects: 2046
Study 35990971 — intervention group
Group type: COMPARATOR
Intervention: Patients with at least one SMuRF
Number of subjects: 2046
Study 35990987 — intervention group
Group type: EXPERIMENTAL
Intervention: LA acceleration factor derived from magnetic resonance (MR) four-dimensional (4D) flow imaging
Number of subjects: 62
Study 35991364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental emergency unit (DEU) intervention during COVID-19
Number of subjects: 299
Study 35992565 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban
Number of subjects: 316
Study 35992565 — intervention group
Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 316
Study 35992822 — intervention group
Group type: EXPERIMENTAL
Intervention: JMT103 at 0.5, 1.0, 2.0, and 3.0 mg/kg every 4 weeks for 3 cycles
Number of subjects: 59
Study 35992850 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnostic model
Number of subjects: 719
Study 35992943 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation contacts
Number of subjects: 31
Study 35992943 — intervention group
Group type: COMPARATOR
Intervention: Ring contacts
Number of subjects: 31
Study 35992943 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation sites
Number of subjects: 31
Study 35992943 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacts in closest proximity to internal capsule
Number of subjects: 31
Study 35992943 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS leads
Number of subjects: 31
Study 35993306 — intervention group
Group type: EXPERIMENTAL
Intervention: Postneoadjuvant treatments (e.g., capecitabine, Olaparib)
Number of subjects: 0
Study 35993306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 35993306 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 3 approaches (e.g., circulating tumour DNA)
Number of subjects: 0
Study 35993829 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral/cushioned running shoes
Number of subjects: 11240
Study 35993829 — intervention group
Group type: COMPARATOR
Intervention: Motion control shoes
Number of subjects: 11240
Study 35993829 — intervention group
Group type: COMPARATOR
Intervention: Soft midsole shoes
Number of subjects: 11240
Study 35993829 — intervention group
Group type: COMPARATOR
Intervention: Stability shoes
Number of subjects: 11240
Study 35993829 — intervention group
Group type: COMPARATOR
Intervention: Running shoes prescribed based on foot posture
Number of subjects: 11240
Study 35994321 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Video Game-based intervention (12 weekly sessions) with game-based pedometers, PA behavioral coaching, and survivorship navigation discussions.
Number of subjects: 60
Study 35994321 — intervention group
Group type: COMPARATOR
Intervention: Control group (existing breast cancer support group) with conventional pedometers.
Number of subjects: 60
Study 35994340 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic video game (TVG) used for 6 weeks
Number of subjects: 15
Study 35994340 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 15
Study 35994340 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic video game (TVG)
Number of subjects: 15
Study 35994729 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) metrics
Number of subjects: 78
Study 35994729 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM metrics from remitters
Number of subjects: 78
Study 35994729 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough CGM analysis
Number of subjects: 78
Study 35994729 — intervention group
Group type: COMPARATOR
Intervention: Residual β-cell secretion estimates
Number of subjects: 78
Study 35994746 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal RBC folate concentrations
Number of subjects: 985
Study 35994746 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal RBC folate concentrations ≥906 nmol/L
Number of subjects: 985
Study 35994746 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization of maternal RBC folate concentrations
Number of subjects: 985
Study 35995129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral NIRS monitoring starting within 6 hours of birth for 72 hours, followed by interventions based on clinical condition.
Number of subjects: 100
Study 35995129 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions following a standard treatment algorithm for persistent cerebral desaturation.
Number of subjects: 100
Study 35995129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral NIRS monitoring.
Number of subjects: 100
Study 35995551 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) thalamotomy
Number of subjects: 100
Study 35995696 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous CIK cells therapy combined with Sintilimab and platinum-based doublet chemotherapy
Number of subjects: 34
Study 35995702 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Number of subjects: 15
Study 35995934 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfection after initial COVID-19 infection
Number of subjects: 1806
Study 35995934 — intervention group
Group type: COMPARATOR
Intervention: Second COVID-19 infections
Number of subjects: 1806
Study 35995934 — intervention group
Group type: COMPARATOR
Intervention: Reinfection mortality
Number of subjects: 1806
Study 35995934 — intervention group
Group type: COMPARATOR
Intervention: Vaccination status before second infection
Number of subjects: 1806
Study 35996071 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model incorporating intraoperative vital signs and preoperative predictors.
Number of subjects: 30619
Study 35996071 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative factors
Number of subjects: 30619
Study 35996071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative predictors
Number of subjects: 30619
Study 35996089 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart-clothes assisted home nursing program (smart-vest)
Number of subjects: 12
Study 35996089 — intervention group
Group type: COMPARATOR
Intervention: Standard care (without smart-vest)
Number of subjects: 12
Study 35996147 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney Disease Index (KDI)
Number of subjects: 9115
Study 35996147 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/eGFR and ln [ACR×100]
Number of subjects: 9115
Study 35996565 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1656 (100mg twice a day)
Number of subjects: 156
Study 35996565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 35996565 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1656
Number of subjects: 156
Study 35996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic Arthritis (PsA) patients with axial involvement
Number of subjects: 2330
Study 35996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic Arthritis (PsA) patients without axial involvement
Number of subjects: 2330
Study 35996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and sulfasalazine (disease-modifying antirheumatic drugs)
Number of subjects: 2330
Study 35996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic Spondylitis patients
Number of subjects: 2330
Study 35996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean patients with PsA requiring biologics
Number of subjects: 2330
Study 35996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic Spondylitis
Number of subjects: 2330
Study 35997582 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV)
Number of subjects: 0
Study 35997582 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (9vHPV)
Number of subjects: 0
Study 35997608 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoacoustic imaging to measure synovial oxygenation status
Number of subjects: 0
Study 35997700 — intervention group
Group type: EXPERIMENTAL
Intervention: Exalt
Number of subjects: 201
Study 35997700 — intervention group
Group type: COMPARATOR
Intervention: aScope Duodeno
Number of subjects: 201
Study 35998100 — intervention group
Group type: EXPERIMENTAL
Intervention: GoNoodle Plus (GN)
Number of subjects: 1098
Study 35998100 — intervention group
Group type: EXPERIMENTAL
Intervention: Take10
Number of subjects: 1098
Study 35998100 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC for Fitness (ABC)
Number of subjects: 1098
Study 35998103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of access to running water
Number of subjects: 1634
Study 35998103 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoke exposure
Number of subjects: 1634
Study 35998103 — intervention group
Group type: COMPARATOR
Intervention: Wood-burning stove use
Number of subjects: 1634
Study 35998103 — intervention group
Group type: COMPARATOR
Intervention: Number of persons living in the household
Number of subjects: 1634
Study 35998103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing loss in children aged 3 to 6 years
Number of subjects: 1634
Study 35998103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing loss in children aged 7 years and older
Number of subjects: 1634
Study 35998103 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle ear disease in children aged 3 to 6 years
Number of subjects: 1634
Study 35998103 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle ear disease in children aged 7 years and older
Number of subjects: 1634
Study 35998206 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day controlled vegetarian diet intervention
Number of subjects: 36
Study 35998303 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 0
Study 35998695 — intervention group
Group type: COMPARATOR
Intervention: Active asthma diagnosis in dairy farmers
Number of subjects: 1203
Study 35998695 — intervention group
Group type: COMPARATOR
Intervention: Family history of allergy
Number of subjects: 1203
Study 35998695 — intervention group
Group type: COMPARATOR
Intervention: Personal history of eczema
Number of subjects: 1203
Study 35998695 — intervention group
Group type: COMPARATOR
Intervention: Hay manipulation
Number of subjects: 1203
Study 35998695 — intervention group
Group type: COMPARATOR
Intervention: Farm area
Number of subjects: 1203
Study 35998695 — intervention group
Group type: COMPARATOR
Intervention: Handling treated seeds
Number of subjects: 1203
Study 35998695 — intervention group
Group type: COMPARATOR
Intervention: Family history of allergy (compared to control non-farm employees)
Number of subjects: 1203
Study 35998959 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident COVID-19
Number of subjects: 16910
Study 35998959 — intervention group
Group type: EXPERIMENTAL
Intervention: Long COVID (defined as symptoms lasting more than 4 weeks after disease onset)
Number of subjects: 16910
Study 35998971 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative mental health intervention bundle (behavioural activation and medication optimisation)
Number of subjects: 0
Study 35999035 — intervention group
Group type: EXPERIMENTAL
Intervention: RRS cluster
Number of subjects: 8266
Study 35999035 — intervention group
Group type: EXPERIMENTAL
Intervention: ULE cluster
Number of subjects: 8266
Study 35999035 — intervention group
Group type: EXPERIMENTAL
Intervention: AD cluster
Number of subjects: 8266
Study 35999035 — intervention group
Group type: EXPERIMENTAL
Intervention: SE cluster
Number of subjects: 8266
Study 35999035 — intervention group
Group type: COMPARATOR
Intervention: Cox-proportional hazard test
Number of subjects: 8266
Study 35999221 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (radiation-attenuated Plasmodium falciparum sporozoites)
Number of subjects: 0
Study 35999221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35999229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 53
Study 35999380 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite mNE
Number of subjects: 575
Study 35999380 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible mNE
Number of subjects: 575
Study 35999380 — intervention group
Group type: COMPARATOR
Intervention: Unexposed
Number of subjects: 575
Study 35999387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 0
Study 35999466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative psychological state (measured by Pain Catastrophizing Score, PCS)
Number of subjects: 266
Study 35999466 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint pain at rest (measured using Visual Analogue Scale 0-100)
Number of subjects: 266
Study 35999466 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms (measured using Beck Depression Inventory or Geriatric Depression Score)
Number of subjects: 266
Study 35999466 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational anxiety and dispositional anxiety (measured using State-Trait Inventory)
Number of subjects: 266
Study 35999466 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint function (assessed using Western Ontario and McMaster Universities Osteoarthritis Index for hip and knee and Oxford Shoulder Score for shoulder)
Number of subjects: 266
Study 35999520 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphate concentration
Number of subjects: 54
Study 35999520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hemodialysis blood pressure measurements
Number of subjects: 54
Study 35999520 — intervention group
Group type: EXPERIMENTAL
Intervention: Total peripheral resistance index (TPRI)
Number of subjects: 54
Study 35999520 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of endothelin-1 (ET-1)
Number of subjects: 54
Study 35999520 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA)
Number of subjects: 54
Study 35999522 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient Fear of Falling (T-FoF)
Number of subjects: 389
Study 35999522 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent Fear of Falling (P-FoF)
Number of subjects: 389
Study 35999522 — intervention group
Group type: COMPARATOR
Intervention: No Fear of Falling (No-FoF)
Number of subjects: 389
Study 35999522 — intervention group
Group type: COMPARATOR
Intervention: T-FoF vs No-FoF
Number of subjects: 389
Study 35999522 — intervention group
Group type: COMPARATOR
Intervention: P-FoF vs No-FoF
Number of subjects: 389
Study 35999522 — intervention group
Group type: COMPARATOR
Intervention: T-FoF vs P-FoF
Number of subjects: 389
Study 35999546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative TyG index (very high group)
Number of subjects: 5695
Study 35999546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative TyG index
Number of subjects: 5695
Study 35999585 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on patient-reported outcome measures (PROMs) in a web-based personalized decision report
Number of subjects: 25
Study 35999616 — intervention group
Group type: EXPERIMENTAL
Intervention: POSITIVE system (home-monitoring equipment and communication platform)
Number of subjects: 50
Study 35999616 — intervention group
Group type: EXPERIMENTAL
Intervention: POSITIVE system
Number of subjects: 50
Study 35999616 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical review, nutritional recommendations, and Vivifrail physical exercise program)
Number of subjects: 50
Study 35999633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-admission telephone reminder
Number of subjects: 262
Study 35999633 — intervention group
Group type: COMPARATOR
Intervention: No pre-admission telephone reminder (non-intervention)
Number of subjects: 262
Study 36000222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (ferrous sulphate, 120 mg elemental iron)
Number of subjects: 15
Study 36000427 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine-mediated G-protein receptor kinase 2 inhibition
Number of subjects: 0
Study 36000427 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36000434 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C ≥100 mg/dL
Number of subjects: 5532
Study 36000434 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C 70-99 mg/dL
Number of subjects: 5532
Study 36000434 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C <70 mg/dL
Number of subjects: 5532
Study 36000434 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 5532
Study 36000699 — intervention group
Group type: EXPERIMENTAL
Intervention: Finalized Actions
Number of subjects: 19
Study 36000699 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Finalized Actions
Number of subjects: 19
Study 36000699 — intervention group
Group type: COMPARATOR
Intervention: Control Videos
Number of subjects: 19
Study 36000699 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching phase of feeding and self-care actions
Number of subjects: 19
Study 36000747 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular adsorbent recirculating system (MARS) treatment
Number of subjects: 10
Study 36000747 — intervention group
Group type: COMPARATOR
Intervention: Historical control cohort (PHLF patients not treated with MARS)
Number of subjects: 10
Study 36000763 — intervention group
Group type: COMPARATOR
Intervention: Listening to music (prerecorded) for 25 to 60 minutes daily for 3 days to 3 months
Number of subjects: 1007
Study 36000763 — intervention group
Group type: COMPARATOR
Intervention: Listening to music (prerecorded)
Number of subjects: 1007
Study 36000783 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional coaching (6 monthly sessions)
Number of subjects: 80
Study 36000783 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (6 monthly sessions after 6 months)
Number of subjects: 80
Study 36000794 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant apalutamide 240 mg once daily for 12 weeks
Number of subjects: 30
Study 36000952 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 90
Study 36001108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg on day 10 and fluconazole 200 mg once daily on days 11-23, with a single oral dose of fedratinib 100 mg on day 18
Number of subjects: 16
Study 36001108 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of fedratinib 100 mg on day 1
Number of subjects: 16
Study 36001116 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodistribution and radiation dosimetry studies
Number of subjects: 3
Study 36001201 — intervention group
Group type: EXPERIMENTAL
Intervention: High relationship control (RC)
Number of subjects: 0
Study 36001201 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle relationship control (RC)
Number of subjects: 0
Study 36001201 — intervention group
Group type: EXPERIMENTAL
Intervention: Low relationship control (RC)
Number of subjects: 0
Study 36001201 — intervention group
Group type: COMPARATOR
Intervention: Sexual Relationship Power Scale (SRPS) and its subscales
Number of subjects: 0
Study 36001228 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg intravenously every 3 weeks)
Number of subjects: 21
Study 36001228 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative SBRT (30-50 Gy delivered daily over five fractions per week)
Number of subjects: 21
Study 36001228 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of palliative SBRT and camrelizumab
Number of subjects: 21
Study 36001236 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit practicing group (exposed group)
Number of subjects: 30
Study 36001294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aralast NP
Number of subjects: 0
Study 36001294 — intervention group
Group type: COMPARATOR
Intervention: Aralast
Number of subjects: 0
Study 36001294 — intervention group
Group type: COMPARATOR
Intervention: Prolastin
Number of subjects: 0
Study 36001426 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous vagus nerve stimulation (atVNS) as an ADD-ON intervention.
Number of subjects: 0
Study 36001430 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use disorder (AUD) patients
Number of subjects: 88
Study 36001430 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstaining AUD patients
Number of subjects: 88
Study 36001430 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsing AUD patients
Number of subjects: 88